Limits...
Eplin-alpha expression in human breast cancer, the impact on cellular migration and clinical outcome.

Jiang WG, Martin TA, Lewis-Russell JM, Douglas-Jones A, Ye L, Mansel RE - Mol. Cancer (2008)

Bottom Line: Grade-2/3 tumours had significantly lower levels of EPLIN-alpha compared with grade-1 (p = 0.047 and p = 0.046 vs grade-1, respectively).Patients with poor prognosis had a significantly lower levels of EPLIN-alpha compared with those with good prognosis (p = 0.0081).It is concluded that expression of EPLIN-alpha in breast cancer is down-regulated in breast cancer cells and tissues, a change linked to the prognosis.

View Article: PubMed Central - HTML - PubMed

Affiliation: Metastasis and Angiogenesis Research Group, Cardiff University School of Medicine, Heath Park, Cardiff CF14 4XN, UK. jiangw@cf.ac.uk

ABSTRACT

Introduction: To investigate the expression of EPLIN-alpha, epithelial protein lost in neoplasm, in human breast cancer tissues/cells and investigate the cellular impact of EPLIN-alpha on breast cancer cells.

Experimental design: EPLIN-alpha was determined in tumour (n = 120) and normal mammary tissues (n = 32), and cancer cell lines (n = 16). Cell invasion, in vitro and in vivo growth of cells transfected with EPLIN-alpha were evaluated using in vitro invasion assay, in vitro and in vivo tumour model. Cellular migration was analysed using Electric Cell Impedance Sensing assays.

Results: Low level of EPLIN-alpha was seen in tumour tissues. Grade-2/3 tumours had significantly lower levels of EPLIN-alpha compared with grade-1 (p = 0.047 and p = 0.046 vs grade-1, respectively). Patients with poor prognosis had a significantly lower levels of EPLIN-alpha compared with those with good prognosis (p = 0.0081). Patients who developed recurrence and died of breast cancer had significantly lower levels of EPLIN-alpha compared with those who remained disease free (p = 0.0003 and p = 0.0008, respectively) (median follow-up 10 years). Patients with high levels of EPLIN-alpha transcript had a longer survival than those with low levels. Over-expression of EPLIN-alpha in breast cancer cells by way of transfection rendered cells less invasive, less motile and growing at a slower pace in vitro and in vivo. An ERK inhibitor was shown to be able to abolish the effect of EPLIN expression.

Conclusion: It is concluded that expression of EPLIN-alpha in breast cancer is down-regulated in breast cancer cells and tissues, a change linked to the prognosis. EPLIN-alpha acts as a potential tumour suppressor by inhibition of growth and migration of cancer cells.

Show MeSH

Related in: MedlinePlus

EPLIN-α expression and impact on in vitro invasion(A), in vitro growth (B) and in vivo tumour growth (C) of breast cancer cells. * p < 0.05 vs respective controls; # p < 0.001 vs control wild type and control groups.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC2553413&req=5

Figure 3: EPLIN-α expression and impact on in vitro invasion(A), in vitro growth (B) and in vivo tumour growth (C) of breast cancer cells. * p < 0.05 vs respective controls; # p < 0.001 vs control wild type and control groups.

Mentions: Using a matrigel based in vitro invasion assay, it was shown that MDA MB231 cells which over-expressed EPLIN-α by way of transfection had significantly reduced invasiveness compared with both wild type and control transfected cells (figure 3A). In vitro cell growth assay showed a significant lower rate of growth of EPLIN-α transfected breast cancer cells (Figure 3B).


Eplin-alpha expression in human breast cancer, the impact on cellular migration and clinical outcome.

Jiang WG, Martin TA, Lewis-Russell JM, Douglas-Jones A, Ye L, Mansel RE - Mol. Cancer (2008)

EPLIN-α expression and impact on in vitro invasion(A), in vitro growth (B) and in vivo tumour growth (C) of breast cancer cells. * p < 0.05 vs respective controls; # p < 0.001 vs control wild type and control groups.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC2553413&req=5

Figure 3: EPLIN-α expression and impact on in vitro invasion(A), in vitro growth (B) and in vivo tumour growth (C) of breast cancer cells. * p < 0.05 vs respective controls; # p < 0.001 vs control wild type and control groups.
Mentions: Using a matrigel based in vitro invasion assay, it was shown that MDA MB231 cells which over-expressed EPLIN-α by way of transfection had significantly reduced invasiveness compared with both wild type and control transfected cells (figure 3A). In vitro cell growth assay showed a significant lower rate of growth of EPLIN-α transfected breast cancer cells (Figure 3B).

Bottom Line: Grade-2/3 tumours had significantly lower levels of EPLIN-alpha compared with grade-1 (p = 0.047 and p = 0.046 vs grade-1, respectively).Patients with poor prognosis had a significantly lower levels of EPLIN-alpha compared with those with good prognosis (p = 0.0081).It is concluded that expression of EPLIN-alpha in breast cancer is down-regulated in breast cancer cells and tissues, a change linked to the prognosis.

View Article: PubMed Central - HTML - PubMed

Affiliation: Metastasis and Angiogenesis Research Group, Cardiff University School of Medicine, Heath Park, Cardiff CF14 4XN, UK. jiangw@cf.ac.uk

ABSTRACT

Introduction: To investigate the expression of EPLIN-alpha, epithelial protein lost in neoplasm, in human breast cancer tissues/cells and investigate the cellular impact of EPLIN-alpha on breast cancer cells.

Experimental design: EPLIN-alpha was determined in tumour (n = 120) and normal mammary tissues (n = 32), and cancer cell lines (n = 16). Cell invasion, in vitro and in vivo growth of cells transfected with EPLIN-alpha were evaluated using in vitro invasion assay, in vitro and in vivo tumour model. Cellular migration was analysed using Electric Cell Impedance Sensing assays.

Results: Low level of EPLIN-alpha was seen in tumour tissues. Grade-2/3 tumours had significantly lower levels of EPLIN-alpha compared with grade-1 (p = 0.047 and p = 0.046 vs grade-1, respectively). Patients with poor prognosis had a significantly lower levels of EPLIN-alpha compared with those with good prognosis (p = 0.0081). Patients who developed recurrence and died of breast cancer had significantly lower levels of EPLIN-alpha compared with those who remained disease free (p = 0.0003 and p = 0.0008, respectively) (median follow-up 10 years). Patients with high levels of EPLIN-alpha transcript had a longer survival than those with low levels. Over-expression of EPLIN-alpha in breast cancer cells by way of transfection rendered cells less invasive, less motile and growing at a slower pace in vitro and in vivo. An ERK inhibitor was shown to be able to abolish the effect of EPLIN expression.

Conclusion: It is concluded that expression of EPLIN-alpha in breast cancer is down-regulated in breast cancer cells and tissues, a change linked to the prognosis. EPLIN-alpha acts as a potential tumour suppressor by inhibition of growth and migration of cancer cells.

Show MeSH
Related in: MedlinePlus